Adults infected with covid-19 three weeks after receiving one dose of the Pfizer-BioNTech or Oxford-AstraZeneca vaccine were 38-49% less likely to pass the virus on to their household contacts than people who were unvaccinated, a preprint released by Public Health England has shown.1 The ...
A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. vaccination efforts.
The response among those previously infected was so effective that it opens the debate as to whether one dose of the vaccine may suffice. "This finding can help countries make informed decisions regarding vaccine policy - for instance, whether those previously infected sho...
The Food and Drug Administration's scientistsconfirmedthat overall the vaccine is about 66% effective at preventing moderate to severe COVID-19. The agency also said J&J's shot — one that could help speed vaccinations by requiring just one dose instead of two — is safe to use. However, J...
'I would much prefer only to have to go in to get my one shot rather than to have to go in a month or three weeks later to get my second shot," he said. Pulendran said a prospective single-dose vaccine would have an "enormous public health impact." ...
PHILADELPHIA (WPVI) -- Studies show the Johnson & Johnson vaccine is safe and 86% effective in preventing severe complications from COVID-19. On Friday, an FDA advisory committee will review those findings and decide if it will grant emergency use authorization. The one-dose Johnson & Johnson...
"The concept of preserving vaccine supply by giving those who have recovered from SARS-CoV2 infection just a single dose of vaccine rather than the usual two-dose regime is a very reasonable idea that may in fact be effective," said Badley, an infectious disease expert. "Today, however, we...
and Ziv Medical Center now report preliminary evidence that people previously infected with the virus responded very strongly to one dose of the Pfizer vaccine, regardless of when they were infected and whether or not they had detectable antibodies against COVID-19 prior to receiving the vaccine. ...
“This means that single-dose vaccine not only takes effect quickly, but also has potential to be effective of vaccination.” One thing to note is that the elderly participants have a higher tolerability for the vaccine whereas they also display a lower level of immune response. ...
Vaccine type:Adenovirus in one dose. Regulatory status:Approved for limited use in China in June, with phase 3 trials ongoing in Mexico, Russia and Pakistan. Production:300m doses in 2021, manufactured in China. Take-up around the world:Likely to be distributed largely in China and Mexico....